Cover Image
市場調查報告書

PCSK9及其他新的高膽固醇症治療藥

PCSK9 and Other Novel Hypercholesterolemia Drugs

出版商 ROOTS ANALYSIS 商品編碼 311926
出版日期 內容資訊 英文 134 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
PCSK9及其他新的高膽固醇症治療藥 PCSK9 and Other Novel Hypercholesterolemia Drugs
出版日期: 2014年09月05日 內容資訊: 英文 134 Pages
簡介

儘管許多降膽固醇藥物上市,統計仍然顯示出較過去更高的高膽固醇疾病負擔。在各種治療選擇中,過去25年Statin製劑都被廣泛使用。但身為主流的降膽固醇藥,Statin製劑卻仍有許多副作用,此外它對家族性高膽固醇血症等患者也無效。

本報告提供核准/已上市,或是開發後期階段的新高膽固醇症治療藥相關調查,提供您高膽固醇症,患病人口,目前治療方法等概要,彙整新的上市藥及開發後期的開發平台藥物概要,作用機制,安全性·有效性,成本,主要產品的短期及長期銷售額預測等資料。

第1章 序文

第2章 摘要整理

第3章 高膽固醇症:主要的問題

  • 關於膽固醇
  • 高膽固醇症
    • 家族性高膽固醇血症
  • LDL膽固醇(LDLC):高膽固醇管理的重要標的
  • 高膽固醇症的患病人口
  • 目前治療性介入與其規定
  • 新的治療藥:PCSK9·其他
  • 成功的障礙
    • 新的膽固醇管理指南
    • 給藥途徑和價格

第4章 目前市場環境

  • 展望·分析
  • 同型連接性家族性高膽固醇血症的2種新治療藥的認證
  • 第一級降膽固醇藥物,在印度核准
  • 同時吸引大規模·小規模經營者的市場
  • 開發最後階段的5種新治療藥
  • 驗證各種分子類型的企業:從合成藥到生技藥品
  • PCSK9抑制劑:最熱門開發中的藥物類別
  • 降膽固醇藥物主要適應病症區域的競爭分析
    • 高膽固醇症/血脂異常症
    • HoFH
    • HeFH

第5章 新上市藥:MTTP抑制劑·Apo B GENE SILENCER

  • 家族性高膽固醇血症的最近重新已批准藥物
  • Juxtapid / Lojuxta(Lomitapide)
    • 概要
    • 結構·作用機制
    • 藥害反應·警告
    • 藥理相互作用
    • 給藥·費用·製造
    • 開發的過程
    • 孤兒藥的現狀
    • 專利
    • 階段III的結果
    • 目前開發情形
    • 聯盟
    • 銷售的過程
  • Kynamro(Mipomersen)
    • 概要
    • 結構·作用機制
    • 專利
    • 反義核酸技術
    • 藥物動力學
    • 藥害反應·警告
    • 給藥·費用·製造
    • 階段III的結果
    • 目前開發情形
    • 聯盟
    • 大獎
  • Mipomersen·Lomitapide:Roots Analysis的展望

第6章 PCSK9抑制劑:主要的分子·未來展望

  • PCSK9抑制劑的發現
  • 作用機制
  • Evolocumab(AMG 145)
  • Alirocumab(REGN727 / SAR236553)
  • Bococizumab(RN-316/PF-04950615)
  • PCSK9抑制劑:Roots Analysis的展望

第7章 CETP抑制劑:主要的分子·未來展望

  • HDL:CETP抑制劑的標的
  • HDL的形成· 膽固醇逆向轉運
  • 提升HDLC的目前治療與新治療藥的必要性
  • CETP的阻礙機制
  • 階段III開發中的CETP抑制劑
  • Anacetrapib
  • CETP抑制劑:Roots Analysis的展望

第8章 整體市場展望

  • 概要
  • 範圍·手法
  • 整體市場預測
  • Juxtapid
    • 短期預測
    • 長期預測
  • Kynamro
    • 短期預測
    • 長期預測
  • Evolocumab
    • 短期預測
    • 長期預測
  • Alirocumab
    • 短期預測
    • 長期預測
  • Bococizumab
    • 短期預測
    • 長期預測
  • Anacetrapib
    • 短期預測
    • 長期預測

第9章 總論

企業清單

圖表

目錄
Product Code: RA10021

Worldwide statistics indicate that there is a high cholesterol burden despite the presence of many cholesterol-lowering drugs in the market. Out of all the available options, statins have been ubiquitously prescribed over the last 25 years. Researchers have concluded that reduction of plasma LDL cholesterol (LDLC) is the cornerstone of assessing heart risk. Irrespective of baseline cholesterol concentration, each mmol/L LDLC reduction translates to cardiovascular risk reduction by one-fifth. Although statins are well tolerated and reduce LDLC levels to the targets specified by NCEP and NICE guidelines, there is a residual cardiovascular risk. Heart diseases are the leading cause of death in the US and most of them are due to high cholesterol.

Statins, though the mainstay therapy for lowering cholesterol, have been associated with some adverse events. These have deterred their use in a subset of population termed as 'Statin Intolerant'. Furthermore, patients with some genetic conditions such as Familial Hypercholesterolemia do not respond to statin therapy. Due to the long historical use of statins and the launch of generics (providing price advantage), the novel drugs will initially target only specific subset of patients for whom statins are clearly not the best treatment option. This need in the market for drugs that work through a different mechanism of action is coupled with a huge opportunity presented by a target population of around 20 million in the US and the EU5 countries.

Synopsis

The 'PCSK9 and Other Novel Hypercholesterolemia Drugs, 2014 - 2024 ' report provides an extensive study of the new class of prescription drugs being evaluated for the treatment of high cholesterol levels caused both by genetic and lifestyle factors.

During the period 2012-2013 three such drugs - Juxtapid, Kynamro, and Lipaglyn - received market authorization; several more novel molecules are in clinical trials. These new drugs have different mechanism of actions: inhibiting or activating genes / proteins in cholesterol metabolism. Examples include PCSK9 inhibitors, CETP inhibitors, MTTP inhibitors, ApoB inhibitors and PPAR agonists. In addition, researchers are also evaluating gene silencing approach.

The report offers an in-depth analysis of four of the five novel classes of drugs mentioned above (PCSK9 inhibitors, MTTP inhibitors, ApoB gene silencers and CETP inhibitors). One of the key objectives is to provide readers a detailed insight into the landscape of novel prescription drugs for treatment of hypercholesterolemia. This is done by:

  • Identifying drug candidates based on their mechanism of cholesterol-lowering actions
  • Reviewing key efficacy and safety parameters for drugs in late-stage clinical trials
  • Reviewing the technologies behind drug-development
  • Understanding drivers and constraints of each drug-class
  • Assessing the competitive landscape, recent market developments such as relevant investments and partnerships
  • Evaluating the development and sales potential for each of the key molecules under consideration

The possibility of a drug to become blockbuster depends on various factors. In addition to safety and efficacy, other factors include cost, mode of administration, side effects and their approval and availability in various geographies. For each of these new classes of drugs, we have highlighted the key drivers and limiting factors. We have also presented our own perspective on how the acceptance and evolution of these drugs is likely to advance in the coming years. The analysis is backed by an extensive review of the hypercholesterolemia / dyslipidemia landscape and familial hypercholesterolemia (HoFH and HeFH) markets.

The base year for the report is 2013. The report provides market forecasts for the following two time horizons: 2014 - 2019 (short-midterm) and 2019 - 2024 (long term), respectively. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

1. With statins going off-patent, pharmaceutical companies are hunting for next blockbusters for hypercholesterolemia. The approval and launch of Kynamro (ISIS Pharmaceuticals / Genzyme) and Juxtapid (Aegerion Pharmaceuticals) in late 2012 / early 2013 has changed the treatment paradigm for homozygous familial hypercholesterolemia. 2. The market for developing novel cholesterol lowering drugs has gained attention of a number of multinational pharmaceutical companies including Amgen, Sanofi, Pfizer, GSK, Eli Lilly, Roche, Johnson & Johnson and more. Overall, there are 27 companies developing 29 molecules in clinical trials. 3. Evolocumab, being developed by Amgen, has been filed with the FDA and EMA for approval. Four more drugs are being evaluated in Phase III clinical trials. Three of these five late stage drugs are PCSK9 inhibitors (monoclonal antibodies), all of which are being developed by large multinational pharmaceutical companies. 4. All three late stage PCSK9 inhibitors are monoclonal antibodies. Other approaches being investigated by drug developers include the use of antisense / siRNA and synthetic molecules. 5. 2015 is likely to witness parallel launch of two anti-PCSK9 mAbs. We expect Evolocumab and Alirocumab to be made commercially available during 2015, while Bococizumab is expected to be available by 2017. 6. Anacetrapib, an oral CETP inhibitor from Merck, can give head to head competition to PCSK9 inhibitors in dyslipidemia / hypercholesterolemia market if the Phase III outcome trial REVEAL shows positive results. 7. In the base scenario, we forecast the market to hit USD 10 billion + sales by 2020. The upside is likely to be higher as the same drugs also start getting evaluated for treatment in the non-US and non-EU5 regions.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Table of Contents

1. PREFACE

  • 1.1 Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. HYPERCHOLESTEROLEMIA: A MAJOR PROBLEM

  • 3.1. Cholesterol: A Primer
  • 3.2. Hypercholesterolemia
    • 3.2.1. Familial Hypercholesterolemia
  • 3.3. LDL Cholesterol (LDLC): An Important Target For High Cholesterol Management
  • 3.4. Population Suffering From Hypercholesterolemia
  • 3.5. Current Therapeutic Interventions and Their Limitations
    • 3.5.1. Statins
    • 3.5.2. Risks Associated With Statins
    • 3.5.3. Lower Reduction of Mortality and High NNT
    • 3.5.4. Other Marketed Drug Classes
  • 3.6. New Emerging Therapies: PCSK9 and Others
  • 3.7. Barriers to Success
    • 3.7.1. New Cholesterol Management Guidelines
    • 3.7.2. Route of Delivery and Price

4. CURRENT MARKET LANDSCAPE

  • 4.1. Scope and Observations
  • 4.2. Two Novel Drugs Approved for Homozygous Familial Hypercholesterolemia
  • 4.3. Another First In Class Cholesterol Lowering Drug Approved in India
  • 4.4. Market Attracting Both Large and Small Pharma Companies
  • 4.5. Five Novel Drugs in Late Stage Development
  • 4.6. Companies Evaluating Different Molecule Types: From Synthetics to Biologics
  • 4.7. PCSK9 Inhibitors: The Most Sought After Drug Class Under Development
    • 4.7.1. PCSK9 Inhibitors Pipeline Analysis
  • 4.8. Competitive Analysis of Key Indication Areas For Cholesterol Lowering Drugs
    • 4.8.1. Hypercholesterolemia/Dyslipidemia Market
    • 4.8.2. HoFH Market
    • 4.8.3. HeFH Market

5. NOVEL MARKETED DRUGS: MTTP INHIBITORS AND Apo B GENE SILENCER

  • 5.1. Recently Approved Drugs for Familial Hypercholesterolemia
  • 5.2. Juxtapid / Lojuxta (Lomitapide)
    • 5.2.1. Overview
    • 5.2.2. Structure and Mechanism of Action
    • 5.2.3. Adverse Reactions and Warnings
    • 5.2.4. Drug Interactions
    • 5.2.5. Dosage, Cost and Manufacturing
    • 5.2.6. History of Development
    • 5.2.7. Orphan Drug Status
    • 5.2.8. Patents
    • 5.2.9. Phase III Results
    • 5.2.10. Current State of Development
    • 5.2.11. Partnerships
    • 5.2.12. Historical Sales
  • 5.3. Kynamro (Mipomersen)
    • 5.3.1. Overview
    • 5.3.2. Structure and Mechanism of Action
    • 5.3.3. Patents
    • 5.3.4. Antisense Technology
    • 5.3.4.1. Overview
    • 5.3.4.2. Patents Covering Technology
    • 5.3.5. Pharmacokinetics
    • 5.3.6. Adverse Reactions and Warnings
    • 5.3.7. Dosage, Cost and Manufacturing
    • 5.3.8. Phase III Results
    • 5.3.9. Current State of Development
    • 5.3.10. Partnerships
    • 5.3.10.1. Genzyme
    • 5.3.10.2. Gilead Sciences
    • 5.3.10.3. Other Collaborations
    • 5.3.11. Awards
    • 5.3.11.1. Breakthrough Alliance Award
    • 5.3.11.2. Partners in Progress Corporate Award
  • 5.4. Mipomersen and Lomitapide: Roots Analysis' Perspective

6. PCSK9 INHIBITORS: KEY MOLECULES AND FUTURE OUTLOOK

  • 6.1. Discovery of PCSK9 Inhibitors
  • 6.2. Mechanism of Action
  • 6.3. Evolocumab (AMG 145)
    • 6.3.1. Overview
    • 6.3.2 Evolocumab has the First Mover Advantage
    • 6.3.3. Current Phase of Development
    • 6.3.4. Drug Delivery Systems Under Review
    • 6.3.5. Partnerships
  • 6.4. Alirocumab (REGN727 / SAR236553)
    • 6.4.1. Overview
    • 6.4.2. Providing Close Competition to Evolocumab with Expedited Review
    • 6.4.3 VelocImmune Technology
    • 6.4.3.1. Overview
    • 7.4.3.2. Patent Portfolio
    • 6.4.4. Current Phase of Development
    • 6.4.5. Drug Delivery Systems Under Review
    • 6.4.6. Partnerships
    • 6.4.6.1. Sanofi Aventis
    • 6.4.6.2. American College of Cardiology (ACC)
    • 6.4.6.3. Academic VelocImmune Investigators' Program
    • 6.4.6.4. Astellas Pharmaceuticals
    • 6.4.6.5. AstraZeneca
  • 6.5 Bococizumab (RN-316/PF-04950615)
    • 6.5.1. Overview
    • 6.5.2. ENHANZE Technology
    • 6.5.3. Current Phase of Development
    • 6.5.4. Drug Delivery Systems under Review
    • 6.5.5. Partnerships
  • 6.6. PCSK9 Inhibitors: Roots Analysis' Perspective

7. CETP INHIBITORS: KEY MOLECULES AND FUTURE OUTLOOK

  • 7.1. HDL: The Target for CETP Inhibitors
  • 7.2. HDL Formation and Reverse Cholesterol Transport
  • 7.3. Current Therapies Raising HDLC and the Need to Develop New Ones
  • 7.4. Mechanism of CETP Inhibition
  • 7.5. CETP Inhibitors in Phase III Development
  • 7.6. Anacetrapib
    • 7.6.1. Overview
    • 7.6.2. Structure
    • 7.6.3. Patent Portfolio
    • 7.6.4. Pharmacokinetics
    • 7.6.5 Current Development Status
  • 7.7. CETP Inhibitors: Roots Analysis' Perspective

8. OVERALL MARKET OUTLOOK

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Overall Market Forecast
  • 8.4. Juxtapid
    • 8.4.1. Sales Forecast, Short-Mid Term (2014 - 2019)
    • 8.4.2. Sales Forecast, Long Term (2019 - 2024)
  • 8.5. Kynamro
    • 8.5.1. Sales Forecast, Short-Mid Term (2014 - 2019)
    • 8.5.2. Sales Forecast, Long Term (2019 - 2024)
  • 8.6. Evolocumab
    • 8.6.1. Sales Forecast, Short-Mid Term (2014 - 2019)
    • 8.6.2. Sales Forecast: Long Term (2019 - 2024)
  • 8.7. Alirocumab
    • 8.7.1. Sales Forecast, Short-Mid Term (2014 - 2019)
    • 8.7.2. Sales Forecast, Long Term (2019 - 2024)
  • 8.8. Bococizumab
    • 8.8.1. Sales Forecast, Short-Mid Term (2014 - 2019)
    • 8.8.2. Sales Forecast, Long Term (2019 - 2024)
  • 8.9. Anacetrapib
    • 8.9.1. Sales Forecast, Short-Mid Term (2014 - 2019)
    • 8.9.2. Sales Forecast, Long Term (2019 - 2024)

9. CONCLUSION

  • 9.1. A Valuable Weapon Against Cardiovascular Diseases
  • 9.2. Statin Refractory and/or Familial Hypercholesterolemia Patients Will be the Key Drivers
  • 9.3. Kynamro and Juxtapid Will Dominate the HoFH Market in Short Term
  • 9.4. Future Growth Hinged Upon Results of Long-term Clinical Safety and Cardiovascular Outcome Studies
  • 9.5 Concluding Remarks

10. APPENDIX 1: TABULATED DATA

11. APPENDIX 2: LIST OF COMPANIES

List of Figures

  • Figure 3.1 Low Density Lipoprotein (LDL) and High Density Lipoprotein (HDL): Comparison
  • Figure 3.2 Forms of Cardiovascular Diseases
  • Figure 3.3 Statins: Mechanism of Action
  • Figure 4.1 Pipeline Analysis: Distribution by Drug Development
  • Figure 4.2 Pipeline Analysis: Distribution by Phase of Development
  • Figure 4.3 Pipeline Analysis: Distribution by Type of Molecule
  • Figure 4.4 Pipeline Analysis: Distribution by Drug Class
  • Figure 4.5 PCSK9 Pipeline Analysis: Distribution by Phase of Development
  • Figure 4.6 PCSK9 Pipeline Analysis: Distribution by Type of Drug
  • Figure 5.1 Structure of Lomitapide
  • Figure 5.2 MTTP Inhibitor and apoB Gene Silencer: Drivers and Restraints
  • Figure 6.1 PCSK9 Inhibitors: Drivers and Restraints
  • Figure 7.1 Anacetrapib: Chemical Structure
  • Figure 7.2 CETP Inhibitors: Drivers and Restraints
  • Figure 8.1 Overall PCSK9 and Other Novel Cholesterol Lowering Drugs Market Forecast: Base Scenario (USD Million)
  • Figure 8.2 Juxtapid Sales Forecast: Short-Mid Term, Base Scenario (2014-2019, USD Million)
  • Figure 8.3 Juxtapid Sales Forecast: Long Term, Base Scenario (2019-2024, USD Million)
  • Figure 8.4 Kynamro Sales Forecast: Short-Mid Term, Base Scenario (2014-2019, USD Million)
  • Figure 8.5 Kynamro Sales Forecast: Long Term, Base Scenario (2019-2024, USD Million)
  • Figure 8.6 Evolocumab Sales Forecast: Short-Mid Term, Base Scenario (2014-2019, USD Million)
  • Figure 8.7 Evolocumab Sales Forecast: Long Term, Base Scenario (2019-2024, USD Million)
  • Figure 8.8 Alirocumab Sales Forecast: Short-Mid Term, Base Scenario (2014-2019, USD Million)
  • Figure 8.9 Alirocumab Sales Forecast: Long Term, Base Scenario (2019-2024, USD Million)
  • Figure 8.10 Bococizumab Sales Forecast: Short-Mid Term, Base Scenario (2014-2019, USD Million)
  • Figure 8.11 Bococizumab Sales Forecast: Long Term, Base Scenario (2019-2024, USD Million)
  • Figure 8.12 Anacetrapib Sales Forecast: Short-Mid Term, Base Scenario (2014-2019, USD Million)
  • Figure 8.13 Anacetrapib Sales Forecast: Long Term, Base Scenario (2019-2024, USD Million)

List of Tables

  • Table 3.1 Cholesterol Levels in HeFH and HoFH
  • Table 3.2 Statins: Efficacy, Sales, and Patent Expiry
  • Table 3.3 Details of Cholesterol Lowering Drugs Other Than Statins
  • Table 4.1 Pipeline of Novel Cholesterol Lowering Drugs, 2014
  • Table 4.2 Marketed and Phase III Drugs: List by Type of Molecule
  • Table 4.3 PCSK9 Inhibitors in Early Stage Development, 2014
  • Table 4.4 Comparison of Drugs in Market and Pipeline for Hypercholesterolemia, 2014
  • Table 4.5 Comparison of Treatment Options Available for HoFH, 2014
  • Table 4.6 Key Phase III Parameters and Results for Kynamro, Juxtapid and Evolocumab
  • Table 4.7 Comparison of Treatment Options Available for HeFH, 2014
  • Table 4.8 Comparison of Drugs under Development for HeFH, 2014
  • Table 5.1 Lomitapide: Pharmacokinetic Properties
  • Table 5.2 Lomitapide: Dosage and Capsule Details
  • Table 5.3 Lomitapide: Approval Timeline
  • Table 5.4 Lomitapide: Patent Portfolio
  • Table 5.5 Lomitapide: Phase III Study for HoFH
  • Table 5.6 Lomitapide: Ongoing Phase III Clinical Trials
  • Table 5.7 Lomitapide: Historical Sales (USD Million)
  • Table 5.8 Mipomersen: Patent Portfolio
  • Table 5.9 Drugs based on Antisense Technology
  • Table 5.10 ISIS Antisense Technology: Patent Portfolio
  • Table 5.11 Mipomersen: Pharmacokinetic Properties
  • Table 5.12 Mipomersen: Completed Phase III Studies
  • Table 5.13 Mipomersen: Ongoing Clinical Trials
  • Table 5.14 Antisense Technology: Partnerships
  • Table 6.1 Evolocumab: Completed Phase III Studies
  • Table 6.2 Evolocumab: Ongoing Clinical Trials
  • Table 6.3 VelocImmune Technology: Antibodies in Pipeline
  • Table 6.4 VelocImmune Technology: Patent Portfolio
  • Table 6.5 Alirocumab: Phase I and Phase II Completed Studies
  • Table 6.6 Alirocumab: Completed Phase III Studies
  • Table 6.7 Alirocumab: Ongoing ODYSSEY Trials
  • Table 6.8 Alirocumab: Interim Results from Phase III Trials
  • Table 6.9 Alirocumab: Other Active Studies
  • Table 6.10 Companies Using ENHANZE Technology
  • Table 6.11 ENHANZE: Patent Portfolio
  • Table 6.12 Bococizumab: Phase I and Phase II Completed Studies
  • Table 6.13 Bococizumab: Phase II Details of NCT01592240
  • Table 6.14 Bococizumab: Active Phase III Studies
  • Table 7.1 Drugs Targeting Increase in HDLC
  • Table 7.2 Phase III CETP Inhibitors: Development Status
  • Table 7.3 Anacetrapib: Patent Portfolio
  • Table 7.4 Pharmacokinetic Properties of Anacetrapib
  • Table 7.5 Anacetrapib: Active Phase III Clinical Trials
  • Table 9.1 Long Term Safety / Efficacy and Outcome Studies
  • Table 10.1 Pipeline Analysis: Distribution by Phase of Development
  • Table 10.2 Pipeline Analysis: Distribution by Type of Molecule
  • Table 10.3 Pipeline Analysis: Distribution by Drug Class
  • Table 10.4 PCSK9 Pipeline Analysis: Distribution by Phase of Development
  • Table 10.5 PCSK9 Pipeline Analysis: Distribution by Type of Drug
  • Table 10.6 Overall PCSK9 and Other Novel Cholesterol Lowering Drugs Market Forecast: Base Scenario (USD Million)
  • Table 10.7 Overall PCSK9 and Other Novel Cholesterol Lowering Drugs Market Forecast: Conservative Scenario (USD Million)
  • Table 10.8 Overall PCSK9 and Other Novel Cholesterol Lowering Drugs Market Forecast: Optimistic Scenario (USD Million)
  • Table 10.9 Juxtapid Sales Forecast: Short-Mid Term, Base Scenario (2014-2019, USD Million)
  • Table 10.10 Juxtapid Sales Forecast: Short-Mid Term, Conservative Scenario (2014-2019, USD Million)
  • Table 10.11 Juxtapid Sales Forecast: Short-Mid Term, Optimistic Scenario (2014-2019, USD Million)
  • Table 10.12 Juxtapid Sales Forecast: Long Term, Base Scenario (2019-2024, USD Million)
  • Table 10.13 Juxtapid Sales Forecast: Long Term, Conservative Scenario (2019-2024, USD Million)
  • Table 10.14 Juxtapid Sales Forecast: Long Term, Optimistic Scenario (2019-2024, USD Million)
  • Table 10.15 Kynamro Sales Forecast: Short-Mid Term, Base Scenario (2014-2019, USD Million)
  • Table 10.16 Kynamro Sales Forecast: Short-Mid Term, Conservative Scenario (2014-2019, USD Million)
  • Table 10.17 Kynamro Sales Forecast: Short-Mid Term, Optimistic Scenario (2014-2019, USD Million)
  • Table 10.18 Kynamro Sales Forecast: Long Term, Base Scenario (2019-2024, USD Million)
  • Table 10.19 Kynamro Sales Forecast: Long Term, Conservative Scenario (2019-2024, USD Million)
  • Table 10.20 Kynamro Sales Forecast: Long Term, Optimistic Scenario (2019-2024, USD Million)
  • Table 10.21 Evolocumab Sales Forecast: Short-Mid Term, Base Scenario (2014-2019, USD Million)
  • Table 10.22 Evolocumab Sales Forecast: Short-Mid Term, Conservative Scenario (2014-2019, USD Million)
  • Table 10.23 Evolocumab Sales Forecast: Short-Mid Term, Optimistic Scenario (2014-2019, USD Million)
  • Table 10.24 Evolocumab Sales Forecast: Long Term, Base Scenario (2019-2024, USD Million)
  • Table 10.25 Evolocumab Sales Forecast: Long Term, Conservative Scenario (2019-2024, USD Million)
  • Table 10.26 Evolocumab Sales Forecast: Long Term, Optimistic Scenario (2019-2024, USD Million)
  • Table 10.27 Alirocumab Sales Forecast: Short-Mid Term, Base Scenario (2014-2019, USD Million)
  • Table 10.28 Alirocumab Sales Forecast: Short-Mid Term, Conservative Scenario (2014-2019, USD Million)
  • Table 10.29 Alirocumab Sales Forecast: Short-Mid Term, Optimistic Scenario (2014-2019, USD Million)
  • Table 10.30 Alirocumab Sales Forecast: Long Term, Base Scenario (2019-2024, USD Million)
  • Table 10.31 Alirocumab Sales Forecast: Long Term, Conservative Scenario (2019-2024, USD Million)
  • Table 10.32 Alirocumab Sales Forecast: Long Term, Optimistic Scenario (2019-2024, USD Million)
  • Table 10.33 Bococizumab Sales Forecast: Short-Mid Term, Base Scenario (2014-2019, USD Million)
  • Table 10.34 Bococizumab Sales Forecast: Short-Mid Term, Conservative Scenario (2014-2019, USD Million)
  • Table 10.35 Bococizumab Sales Forecast: Short-Mid Term, Optimistic Scenario (2014-2019, USD Million)
  • Table 10.36 Bococizumab Sales Forecast: Long Term, Base Scenario (2019-2024, USD Million)
  • Table 10.37 Bococizumab Sales Forecast: Long Term, Conservative Scenario (2019-2024, USD Million)
  • Table 10.38 Bococizumab Sales Forecast: Long Term, Optimistic Scenario (2019-2024, USD Million)
  • Table 10.39 Anacetrapib Sales Forecast: Short-Mid Term, Base Scenario (2014-2019, USD Million)
  • Table 10.40 Anacetrapib Sales Forecast: Short-Mid Term, Conservative Scenario (2014-2019, USD Million)
  • Table 10.41 Anacetrapib Sales Forecast: Short-Mid Term, Optimistic Scenario (2014-2019, USD Million)
  • Table 10.42 Anacetrapib Sales Forecast: Long Term, Base Scenario (2019-2024, USD Million)
  • Table 10.43 Anacetrapib Sales Forecast: Long Term, Conservative Scenario (2019-2024, USD Million)
  • Table 10.44 Anacetrapib Sales Forecast: Long Term, Optimistic Scenario (2019-2024, USD Million)

Listed Companies

The following companies and organisations have been mentioned in this report.

  • 1. Aegerion Pharmaceuticals
  • 2. Alnylam Pharmaceuticals
  • 3. American College of Cardiology
  • 4. American Heart Association
  • 5. Amgen
  • 6. Astellas Pharma
  • 7. AstraZeneca
  • 8. AtheroNova Inc.
  • 9. Baxter International
  • 10. Biogen Idec
  • 11. Bristol Myers Squibb
  • 12. British Heart Foundation
  • 13. Catabasis Pharmaceuticals
  • 14. Catalent Pharma Solutions
  • 15. Cerenis Therapeutics
  • 16. Cymabay Therapeutics
  • 17. Daiichi Sankyo
  • 18. Deloitte
  • 19. Dozima Pharma
  • 20. Eli Lilly
  • 21. EMA
  • 22. Esperion Therapeutics
  • 23. Excaliard Pharmaceuticals
  • 24. FDA
  • 25. Genzyme
  • 26. Gilead Sciences
  • 27. GlaxoSmithKline
  • 28. Halozyme Therapeutics
  • 29. Hospira
  • 30. Idera Pharmaceuticals
  • 31. Intrexon
  • 32. ISIS Pharmaceuticals
  • 33. Johnson & Johnson
  • 34. Kowa
  • 35. LipimetiX
  • 36. Lupin Pharmaceuticals
  • 37. Madrigal Pharmaceuticals
  • 38. Merck
  • 39. Meridian Medical Technologies
  • 40. Mitsubishi Tanabe
  • 41. NHLBI (National Heart, Lung, and Blood Institute)
  • 42. Novartis
  • 43. Pfizer
  • 44. Regeneron
  • 45. Resverlogix
  • 46. Roche
  • 47. Sandoz Pharmaceuticals
  • 48. Sanofi
  • 49. Santaris Pharma
  • 50. Serometrix
  • 51. Shifa Biomedical
  • 52. Upsher Smith Laboratories
  • 53. Viropharma
  • 54. Xenon Pharmaceuticals
  • 55. Zhejiang Hisun Chemical
  • 56. Zydus Cadilla
Back to Top